Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease

<h4>Background</h4> Dual antiplatelet therapy (DAPT) is currently the standard treatment for the prevention of ischemic events after stent implantation. However, the optimal DAPT duration remains elusive for patients with chronic kidney disease (CKD). Therefore, we aimed to compare the e...

Full description

Bibliographic Details
Main Authors: Chih-Chin Kao, Mai-Szu Wu, Ming-Tsang Chuang, Yi-Cheng Lin, Chun-Yao Huang, Wei-Chiao Chang, Chih-Wei Chen, Tzu-Hao Chang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336855/?tool=EBI
id doaj-5da4d20c58984c95b1466becdea33074
record_format Article
spelling doaj-5da4d20c58984c95b1466becdea330742021-08-08T04:31:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01168Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney diseaseChih-Chin KaoMai-Szu WuMing-Tsang ChuangYi-Cheng LinChun-Yao HuangWei-Chiao ChangChih-Wei ChenTzu-Hao Chang<h4>Background</h4> Dual antiplatelet therapy (DAPT) is currently the standard treatment for the prevention of ischemic events after stent implantation. However, the optimal DAPT duration remains elusive for patients with chronic kidney disease (CKD). Therefore, we aimed to compare the effectiveness and safety between long-term and short-term DAPT after coronary stenting in patients with CKD. <h4>Methods</h4> This retrospective cohort study analyze data from the Taipei Medical University (TMU) Institutional and Clinical Database, which include anonymized electronic health data of 3 million patients that visited TMU Hospital, Wan Fang Hospital, and Shuang Ho Hospital. We enrolled patients with CKD after coronary stenting between 2008 and 2019. The patients were divided into the long-term (>6 months) and short-term DAPT group (≤ 6 months). The primary end point was major adverse cardiovascular events (MACE) from 6 months after the index date. The secondary outcomes were all-cause mortality and Thrombolysis in Myocardial Infarction (TIMI) bleeding. <h4>Results</h4> A total of 1899 patients were enrolled; of them, 1112 and 787 were assigned to the long-term and short-term DAPT groups, respectively. Long-term DAPT was associated with similar risk of MACE (HR: 1.05, 95% CI: 0.65–1.70, P = 0.83) compare with short-term DAPT. Different CKD risk did not modify the risk of MACE. There was also no significant difference in all-cause mortality (HR: 1.10, 95% CI: 0.75–1.61, P = 0.63) and TIMI bleeding (HR 1.19, 95% CI: 0.86–1.63, P = 0.30) between groups. <h4>Conclusions</h4> Among patients with CKD and coronary stenting, we found that long-term and short-term DAPT tied on the risk of MACE, all-cause mortality and TIMI bleeding.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336855/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Chih-Chin Kao
Mai-Szu Wu
Ming-Tsang Chuang
Yi-Cheng Lin
Chun-Yao Huang
Wei-Chiao Chang
Chih-Wei Chen
Tzu-Hao Chang
spellingShingle Chih-Chin Kao
Mai-Szu Wu
Ming-Tsang Chuang
Yi-Cheng Lin
Chun-Yao Huang
Wei-Chiao Chang
Chih-Wei Chen
Tzu-Hao Chang
Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease
PLoS ONE
author_facet Chih-Chin Kao
Mai-Szu Wu
Ming-Tsang Chuang
Yi-Cheng Lin
Chun-Yao Huang
Wei-Chiao Chang
Chih-Wei Chen
Tzu-Hao Chang
author_sort Chih-Chin Kao
title Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease
title_short Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease
title_full Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease
title_fullStr Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease
title_full_unstemmed Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease
title_sort investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2021-01-01
description <h4>Background</h4> Dual antiplatelet therapy (DAPT) is currently the standard treatment for the prevention of ischemic events after stent implantation. However, the optimal DAPT duration remains elusive for patients with chronic kidney disease (CKD). Therefore, we aimed to compare the effectiveness and safety between long-term and short-term DAPT after coronary stenting in patients with CKD. <h4>Methods</h4> This retrospective cohort study analyze data from the Taipei Medical University (TMU) Institutional and Clinical Database, which include anonymized electronic health data of 3 million patients that visited TMU Hospital, Wan Fang Hospital, and Shuang Ho Hospital. We enrolled patients with CKD after coronary stenting between 2008 and 2019. The patients were divided into the long-term (>6 months) and short-term DAPT group (≤ 6 months). The primary end point was major adverse cardiovascular events (MACE) from 6 months after the index date. The secondary outcomes were all-cause mortality and Thrombolysis in Myocardial Infarction (TIMI) bleeding. <h4>Results</h4> A total of 1899 patients were enrolled; of them, 1112 and 787 were assigned to the long-term and short-term DAPT groups, respectively. Long-term DAPT was associated with similar risk of MACE (HR: 1.05, 95% CI: 0.65–1.70, P = 0.83) compare with short-term DAPT. Different CKD risk did not modify the risk of MACE. There was also no significant difference in all-cause mortality (HR: 1.10, 95% CI: 0.75–1.61, P = 0.63) and TIMI bleeding (HR 1.19, 95% CI: 0.86–1.63, P = 0.30) between groups. <h4>Conclusions</h4> Among patients with CKD and coronary stenting, we found that long-term and short-term DAPT tied on the risk of MACE, all-cause mortality and TIMI bleeding.
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336855/?tool=EBI
work_keys_str_mv AT chihchinkao investigationofdualantiplatelettherapyaftercoronarystentinginpatientswithchronickidneydisease
AT maiszuwu investigationofdualantiplatelettherapyaftercoronarystentinginpatientswithchronickidneydisease
AT mingtsangchuang investigationofdualantiplatelettherapyaftercoronarystentinginpatientswithchronickidneydisease
AT yichenglin investigationofdualantiplatelettherapyaftercoronarystentinginpatientswithchronickidneydisease
AT chunyaohuang investigationofdualantiplatelettherapyaftercoronarystentinginpatientswithchronickidneydisease
AT weichiaochang investigationofdualantiplatelettherapyaftercoronarystentinginpatientswithchronickidneydisease
AT chihweichen investigationofdualantiplatelettherapyaftercoronarystentinginpatientswithchronickidneydisease
AT tzuhaochang investigationofdualantiplatelettherapyaftercoronarystentinginpatientswithchronickidneydisease
_version_ 1721216493579927552